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Abstract
Background: The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother
has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed
to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1)
before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of
the Step 2 PCT on child symptoms after the Step 1 treatment.
Methods: The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study
design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: intensive treatment of the mother
including psychotherapy and pharmacotherapy; Step 1 control group [CG]: supportive counseling only for mother;
Step 2 TG and CG: PCT). Single- and multi-group analyses with piecewise linear latent growth curve models were
applied to test for the effects of group and phase. Child symptoms (e.g., ADHD symptoms, disruptive behavior) were
rated by three informants (blinded clinician, mother, teacher).
Results: Children in the TG showed a stronger improvement of their disruptive behavior as rated by mothers
than those in the CG during Step 1 (Step 1: TG vs. CG). In the CG, according to reports of the blinded clinician and the
mother, the reduction of children’s disruptive behavior was stronger during Step 2 than during Step 1 (CG: Step 1 vs.
Step 2). In the TG, improvement of child outcome did not differ across treatment steps (TG: Step 1 vs. Step 2).
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Conclusions: Intensive treatment of the mother including pharmacotherapy and psychotherapy may have small positive
effects on the child’s disruptive behavior. PCT may be a valid treatment option for children with ADHD regarding
disruptive behavior, even if mothers are not intensively treated beforehand.
Trial registration: ISRCTN registry ISRCTN73911400. Registered 29 March 2007.
Keywords: Mothers, Children, Adult treatment, Parent training, Efficacy
Background
The general efficacy of behavioral interventions for children
with attention-deficit/hyperactivity disorder (ADHD), in-
cluding parent training, has been comprehensively investi-
gated [1–3]. However, as treatment success varies across
families [4], several studies investigated the moderat-
ing role of parental ADHD in the efficacy of behav-
ioral parent training. This introduction builds in part
on two comprehensive reviews summarizing the find-
ings from this research area [5, 6].
The heritability of ADHD is high [7] and many children
with ADHD have parents who show ADHD symptoms
themselves [8, 9]. Furthermore, parents with ADHD are
more likely to have deficits in parenting than parents with-
out ADHD [10–12].
Most importantly, parental ADHD has been linked to
reduced efficacy of behavioral parent training. Diminished
effects have been reported for child ADHD symptoms and
behavioral problems [13, 14] as well as for parenting [13,
15]. However, there are also studies reporting no deterior-
ating effect of parental ADHD on child benefit from treat-
ment [13, 15, 16], which may at least partly be explained
by less affected parents and more personalized treatment
approaches in the respective studies [5].
For adults with ADHD, the current first-line treat-
ment option is pharmacotherapy [17, 18]. Effect sizes of
stimulants on ADHD symptoms are in the medium to
large range [19, 20] and are comparable to those
reported for children and adolescents [21]. Cognitive
behavioral therapy has been less intensively investigated
[18, 22], but the available evidence shows some positive
findings [23–26].
Treatment of ADHD in adults (pharmacotherapy, cogni-
tive behavioral therapy) may also affect parenting and child
outcome. Only a small number of trials have investigated
this issue with regard to pharmacotherapy. The current
evidence is mixed [27–29] and it has been suggested that
the effects of pharmacotherapy on parenting might be lim-
ited and insufficient [5]. To our knowledge, the effects of
cognitive-behavioral interventions in adults have not yet
been evaluated with respect to child outcomes.
Some studies tested the combined effect of parent
ADHD treatment and behavioral parent training in terms
of improving child outcome [30–32]. In such cases, the
adult treatment might serve two different purposes: First,
it may have a (limited) more or less direct effect on par-
enting and on child outcome (via parenting); and second,
improvements in neurocognitive functioning might help
parents to participate in and benefit from the training
(e.g., sustaining attention during the sessions) and to fulfill
accompanying requirements (e.g., homework).
In a study by Babinski et al. [30], the combination of
pharmacotherapy for adults and behavioral parent train-
ing revealed no treatment advantage over behavioral par-
ent training alone with regard to observed parenting and
child behavior. However, parents only received stimu-
lants before and after the parent training intervention
period. Therefore, the study was able to provide infor-
mation about the short-term effects of stimulants on
parenting, but not about the potential treatment advan-
tage of medication for training participation.
The AIMAC (ADHD in Mothers and Children) study
tested the efficacy of combined mother and child
ADHD treatment in a randomized controlled trial with
an active control group [32–34]. In the first phase (Step
1), mothers of the treatment group (TG) received group
psychotherapy plus stimulant medication, while
mothers of the control group (CG) received supportive
counseling only. In the second phase (Step 2), treat-
ment of the mother was maintained and mothers of
both groups were additionally provided with the same
individual parent-child training. The results revealed
that after Step 2, mothers of the TG showed a stronger
ADHD symptom reduction, but no group differences
were detected regarding children’s ADHD symptoms
and disruptive behavior [32].
The current study constitutes a supplemental analysis
of the AIMAC study by Jans et al. [32]. The previous
main analysis focused on the comparison of the CG
and TG (between-group analysis) concerning the com-
bined effect of the mother and child treatment. As the
main analysis revealed no group differences on import-
ant child domains, the present re-analysis aimed to es-
tablish the relative importance of the two treatment
phases (Step 1, Step 2). For this purpose, the observed
total change was split not only by group but also by
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treatment phase. Comparisons were conducted between
groups (Step 1: CG vs. TG; Step 2: CG vs. TG) as well
as within groups (CG: Step 1 vs. Step 2; TG: Step 1 vs.
Step 2). The latter analyses served as a type of within-
group control design (e.g., stronger child symptom re-
duction during Step 2 compared to Step 1 would have
been considered as evidence for the efficacy of the
parent-child training).
We were particularly interested in two research ques-
tions (primary testing approach in parentheses): (i) Is
parent-child training useful for mothers with ADHD who
have been minimally or intensively treated beforehand
(CG: Step 1 vs. Step 2; TG: Step 1 vs. Step 2)? (ii) Do chil-
dren benefit from intensive pharmacological and psycho-
logical treatment of the mother (Step 1: TG vs. CG)?
The first question concerned the efficacy and import-
ance of the parent-child training in the treatment
groups, a subject that is crucial for treatment planning
and that is unresolved with regard to mothers with
ADHD. On the one hand, for parents with ADHD, the
efficacy of parent-child training has been called into
question and is often considered to be reduced; on the
other hand, non-significant findings have also been re-
ported, and it has been suggested that for personalized
parent training, the treatment effects might not be
attenuated even in mothers with ADHD [5]. Further-
more, the main analysis of the AIMAC study did not
reveal group differences on important child domains,
despite the successful treatment of the mothers of the
TG (e.g., ADHD symptoms, disruptive behavior) [32].
Contrary to our own previous hypotheses, we therefore
assumed post hoc that the parent-child treatment actu-
ally did work in both treatment groups due to the indi-
vidualized approach. Particularly for the CG, where the
mother’s treatment was of low intensity, we expected
the within-group control comparison to be significant,
meaning that we would find a stronger symptom reduc-
tion during the Step 2 parent-child training than during
the Step 1 treatment of the mother (CG: Step 1 vs. Step
2). For the TG, we also considered the parent-child
training to be effective. However, regarding the within-
group comparison (TG: Step 1 vs. Step 2), clear hypoth-
eses were more difficult to derive for the TG, as here,
the Step 1 treatment of the mother was more intense
and at least for pharmacotherapy in adults, (limited)
effects on parenting and child symptoms have been
reported [27, 29]. We thus considered it more likely
that a more homogenous and less distinct pattern of
change would be observed across the treatment phases
for the TG (TG: Step 1 vs. Step 2) and therefore, if add-
itional effects were to be observed, we expected them
to be rather small.
The second research question concerned the effects of
the pharmacotherapy and psychological treatment of the
mothers in the TG on the child’s symptoms when com-
pared with supportive counseling for the mother (Step 1:
TG vs. CG). ADHD pharmacotherapy for adults has
shown some positive indirect effects on their children,
but the sustainability of the impact has been questioned
[5]. To our knowledge, the effect of adult psychotherapy
on children has not been investigated so far, and nor has
the combination of pharmacotherapy and psychotherapy
been tested. We consider this to be the first trial to in-
vestigate this subject using a randomized design (Step 1:
TG vs. CG). Due to the indirect effect of the treatment
on the child, we expected to find rather small effects in
favor of the TG.
Methods
Design
The design consisted of a blinded randomized multicen-
ter parallel-group trial with two treatment arms (TG,
CG). Families were allocated to the treatment arms by
block randomization at a ratio of 1:1 and were stratified
by center.
Sites
The trial was conducted at five specialized units of uni-
versity hospitals in Germany (Berlin, Freiburg, Homburg,
Mannheim, Würzburg) and was coordinated by the Uni-
versity Hospital of Würzburg. Families were primarily
recruited from patients who were referred to the hospi-
tals but were also recruited via local child psychiatrists
and newspaper and website advertising.
Inclusion and exclusion criteria
Inclusion and exclusion criteria concerned mothers and
their children and have been reported in detail elsewhere
[32–34]. Mothers had to fulfill the following inclusion
criteria: (a) age 18 to 60 years; (b) diagnosis of ADHD
according to the Diagnostic and Statistical Manual of
Mental Disorders (4th ed.; DSM-IV) [35]; (c) a score ≥
30 on the Wender Utah Rating Scale, German short ver-
sion (WURS-K) [36]. Exclusion criteria for mothers
were: (a) IQ < 85; (b) psychotherapy for ADHD, methyl-
phenidate treatment or parent-child training within the
last 6 months before baseline assessment; (c) current
psychotherapeutic or psychopharmacological treatment,
(d) methylphenidate intolerance; (e) indication for
inpatient treatment; (f ) insufficient German language
skills; (g) severe comorbid psychological disorder (e.g.,
schizophrenia, bipolar disorder); (h) medical contraindi-
cation (e.g., seizures, thyroid function, pregnancy).
Child inclusion criteria were: (a) age 6 to 12 years; (b)
diagnosis of ADHD according to DSM-IV criteria; (c) no
medication or stable medication for at least 4 weeks
before baseline assessment. Exclusion criteria were: (a)
IQ ≤ 80; (b) indication for inpatient treatment; (c)
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insufficient German language skills; (d) severe comor-
bid psychological disorder (e.g., pervasive develop-
mental disorder, psychosis).
Sample
The AIMAC study sample has been described in detail
elsewhere [32, 34]. Briefly, during the trial, 444 families
were contacted and pre-screened, 206 were assessed for
eligibility, and 144 families were randomized. The
current analysis is based on the full analysis set (FAS),
considering only families with the primary outcome
(child’s combined ADHD-ODD score) available at base-
line (n = 143) [32].
Across the treatment groups, mothers were on average
38.30 (SD = 5.70) years old. Regarding DSM-IV ADHD
diagnoses, 65.7% showed the combined type, 23.8% the
predominantly inattentive type and 10.5% the predomin-
antly hyperactive-impulsive type. At least one current or
past comorbid disorder was detected in 71.3% of the
mothers, with a single episode of major depressive dis-
order (26.6%) and recurrent major depressive disorder
(21.7%) being the most prevalent conditions. Prior to the
start of the study, 55.9% of the mothers had already
received psychiatric or psychotherapeutic treatment and
14.0% had been previously treated with some stimulant
medication (methylphenidate, amphetamine, other) and
0.7% had been prescribed atomoxetine.
In the FAS sample, children were predominantly male
(73.4%) and were on average 9.44 (SD = 1.71) years old.
With respect to the DSM-IV diagnosis of ADHD, 52.4%
of the children showed the combined type, 39.2% the
predominantly inattentive type and 8.4% the predomin-
antly hyperactive-impulsive type. At least one current co-
morbid disorder was apparent in about half of the
children (47.6%), with oppositional defiant disorder
(ODD) being the most prevalent condition (30.1%). Prior
to the start of the trial, 81.1% of the children had received
psychiatric or psychological treatment. Furthermore,
53.8% had previously received stimulant medication
(methylphenidate, amphetamine, other) and 2.8% had
been treated with atomoxetine. During the trial, 74.8% of
the children received ongoing psychopharmacological
medication that had been prescribed before the start of
the study and was to be kept stable.
Intervention
Intervention steps
The intervention comprised three steps in both inter-
vention arms (Step 1, Step 2, Step 3; see Additional file 1:
Figure S1). Step 1 served for the treatment of the
mothers and lasted for 3 months. Mothers of the TG
received multimodal treatment for adults with ADHD
(group psychotherapy, psychopharmacotherapy) while
mothers of the CG received supportive counseling. In
Step 2, the treatment of the mothers was continued and
the parent-child training began. The second period also
lasted for 3 months, and the treatment protocol of the
parent-child training was identical for both the TG and
CG. Step 3 lasted for 6 months and served as a mainten-
ance period for mother and child treatment.
Treatment for mothers was on a weekly basis (12 ses-
sions) during Step 1 and every 4 weeks thereafter (10
sessions during Step 2 and Step 3). Parent-child training
during Step 2 was scheduled every week (12 sessions)
and two booster sessions were offered thereafter (Step
3). For reasons of simplicity, in the following, the Step 1
treatment phase is called mother treatment and the Step
2 treatment phase is called parent-child training.
ADHD treatment for mothers – TG
Group psychotherapy for mothers of the TG was based
on a treatment manual founded in cognitive behavioral
therapy and dialectical behavior therapy [25, 37]. Topics
of the sessions are psychoeducation, mindfulness train-
ing, organizational skills, self-management, emotional
regulation, impulse control, stress management and
interpersonal problems. Each session was planned to last
for 2 h, with groups comprising six to nine parents, and
to include homework. Based on the needs of each
patient, up to three individual sessions were offered.
Mothers of the TG additionally received pharmaco-
logical treatment with long-acting methylphenidate
(Medikinet® retard) [38]. Therapy was started with 10
mg/d and was individually adjusted to daily dosages of
up to 1.3 mg/kg. Multiple dosages per day were allowed.
ADHD treatment for mothers – CG
Mothers of the CG received individual supportive coun-
seling. Sessions lasted for 15 to 20min and topics were
based on the individual needs of the mothers. Counsel-
ing was conducted in a non-directive manner and
mothers were encouraged to find solutions to their
problems on their own.
ADHD treatment for children
Parent-child training was based on the German treat-
ment manual THOP (Therapieprogramm für Kinder mit
hyperkinetischem und oppositionellem Problemverhal-
ten [Therapy program for children with hyperkinetic
and oppositional problem behavior]) [39] for children
with hyperkinetic and oppositional problem behavior,
which has been shown to be effective in the short term
and have lasting effects in the long term [40–42]. The
treatment included the following topics: developmental
model of behavioral problems, identification of most
concerning child problems, enhancing positive parent-
child interaction, rules, effective commands, positive
consequences and negative consequences, time-out and
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token economy [40]. The individual training was held in
1-h sessions and focused primarily on mothers and their
children; however, fathers and teachers were included
whenever needed and feasible.
Assessment and informants
Assessments were conducted at baseline (T1), immedi-
ately after Step 1 about 3 months from baseline (T2),
after Step 2 about 6 months from baseline (T3), and
after the Step 3 maintenance period about 12 months
from baseline (T4). A follow-up assessment took place
after a maintenance period of approximately 1 year (T5).
The current analysis concerned the assessments T1 to
T3, which spanned Step 1 (T1–T2) and Step 2 (T2–T3).
Other measurement occasions were disregarded as not
all outcome measures of analysis were collected at all
assessment points.
The analysis included the ratings of three informants
(blinded clinician, mother, teacher). The blinded clin-
ician was not involved in the treatment and conducted
clinical interviews with the mother and the child. Her or
his rating was blind to the treatment condition, but
given the nature of interviews with families, blindness to
the time of the assessment may not have been ensured
in all cases.
Outcome measures
Assessment of child symptoms
The selection of instruments considered for this analysis
concerned child externalizing behavior and its impact on
the family, including reports of all three informants
(blinded clinician, mother, teacher).
Kiddie-Sads-Present and Lifetime Version (K-SADS)
The K-SADS is a semi-structured interview developed to
assess psychopathology in children aged 6 to 18 years
[43, 44]. It was conducted by the blinded clinician, who
interviewed mothers and children separately regarding
the child’s behavior during the past 2 weeks. Besides cat-
egorical diagnostics, the interview can also be used for
dimensional assessment [45]. The three scales Inatten-
tion (Inattention; nine items), Hyperactivity/Impulsivity
(Hyp/Imp; nine items) and Oppositional Defiant
Disorder (ODD; eight items) are reported.
Strengths and Difficulties Questionnaire (SDQ)
The SDQ is a questionnaire to assess behaviors, emo-
tions and relationships in children [46]. The version for
parents and teachers of children aged 4 to 17 years was
used and was rated by both informants. For this analysis,
the scales Hyperactivity (Hyperactivity; five items),
Conduct Problems (Conduct; five items) and Emotional
Symptoms (Emotional; five items) are reported.
Home Situation Questionnaire (HSQ)
The HSQ is a questionnaire to assess externalizing be-
havior of children in specific situations [47, 48]. Items
were rated by mothers, and the total scale (Total; 16
items) was used.
Family Impact Questionnaire (FIQ)
The FIQ is a questionnaire to measure the impact of child
externalizing behavior on family functioning [49]. Results
of three scales Impact on Social Life (Social; 11 items),
Positive Feelings Toward Child (Positive; seven items) and
Negative Feelings Toward Child (Negative; nine items)
based on ratings of the mothers are reported.
Assessment of maternal symptoms
The instruments concerned the ADHD symptoms of the
mothers. Reports of the blinded clinician and the mothers
were considered.
Conners’ Adult ADHD Rating Scales–Observer: Long Version
(CAARS–O)
The CAARS–O are designed to assess ADHD symptom
domains in adults rated by significant others (e.g., rela-
tives, professionals) [50]. For the study, the question-
naire was completed by the blinded clinician. Results of
the subscales Inattention and Memory Problems (In-
attention; 12 items), Hyperactivity/Restlessness (Hyper-
activity; 12 items) and Impulsivity/Emotional Lability
(Impulsivity; 12 items) are reported.
Conners’ Adult ADHD Rating Scales–Self-Report: Long
Version (CAARS–S)
The CAARS–S were developed analogously to the
CAARS–O [50] and were rated by the mothers.
Statistical analysis
All analyses were performed using the statistical software
R (Version 3.4) [51], and for structural equation modeling
in particular, the specific R package lavaan was used (Ver-
sion 0.5) [52]. Change over time was investigated by piece-
wise latent growth models [53, 54]. The TG and CG were
first analyzed separately (single-group analysis) and then
jointly (multi-group analysis; for a graphical representa-
tion, see Additional file 1: Figure S2). To describe the
growth process, three latent variables were considered for
each treatment group, one random intercept and two
fixed slope factors. The means of the first fixed slope
factor (CG: αðCGÞ2 ; TG: α
ðTGÞ
2 ) represented the change dur-
ing the Step 1 treatment of the mother in each of the
treatment groups (T1 to T2), and the means of the second
fixed slope factor (CG: αðCGÞ3 ; TG: α
ðTGÞ
3 ) indicated the
change during the Step 2 parent-child training (T2 to T3).
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The mean of the random intercept factor (CG: αðCGÞ1 ; TG:
αðTGÞ1 ) represented the average outcome at baseline (T1).
During the modeling process, a series of nested models
were analyzed to test for differences among factor means
(null hypotheses [H0] in parentheses). The first step of the
analysis (single-group analysis) focused on the comparison
of the Step 1 change with the Step 2 change in the
respective treatment groups (within-group analysis; CG
H0: α
ðCGÞ
2 = α
ðCGÞ
3 ; TG H0: α
ðTGÞ
2 = α
ðTGÞ
3 ). For each treat-
ment group, two models were analyzed and compared by
a Chi-square difference test, one with the means of the
two slope factors freely estimated and one with the means
constrained to be equal. Equal growth rates would indicate
that the observed change during the Step 1 treatment of
the mother and the Step 2 parent-child training did not
significantly differ and consequently, that no additional ef-
fect of the parent-child training could be shown in a par-
ticular treatment group.
In the next step of the examination, the treatment groups
were tested jointly (multi-group analysis) in order to con-
duct comparisons among them (between-group analysis).
The analysis was based on the final models of the former
single-group analyses. The purpose of the between-group
analysis was to compare the change rates in the CG and
TG during the Step 1 treatment of the mother (H0: α
ðCGÞ
2 =
αðTGÞ2 ) as well as to compare the change rates among the
treatment groups during the Step 2 parent-child training
(H0: α
ðCGÞ
3 = α
ðTGÞ
3 ). The Step 1 comparison was of particu-
lar interest, because it served as a test for the efficacy of the
intensive treatment of the mother in the TG relative to the
CG. The analytical procedure was analogous to the
within-group comparison; models with freely estimated
means and models with the means constrained to be equal
were estimated and were compared by Chi-square differ-
ence test. In this case, equal growth rates would show that
the change during a respective treatment period was com-
parable between the groups. The between-group analysis
additionally included a comparison of the means of the
intercept factors in the CG and TG (H0: α
ðCGÞ
1 = α
ðTGÞ
1 ),
which served as a test for differences at the beginning of
the treatment (T1).
Results for standardized variables as well as unstan-
dardized variables (see Additional file 1) are reported.
For standardization, a z-transformation was conducted
with the grand mean and the grand standard devi-
ation over time and group of all available data [55].
The transformation was conducted to increase the
interpretability of the coefficients. Given this type of
standardization and the fact that the means of the
two slope factors represented the average change dur-
ing Step 1 and Step 2, we interpreted them like a
Cohen’s d effect size measure.
Model fit was considered satisfactory when, for the
Chi-square (χ2) test, p > .05 and the comparative fit
index (CFI) > .90. The root mean square error of ap-
proximation (RMSEA) was not used, because all models
had small degrees of freedom and, moreover, had a small
sample size [56]. Missing data were handled by full-in-
formation maximum likelihood [57]. For a person to be
considered for analysis, at least one of the three
assessment points (T1–T3) had to be available.
Results
Descriptive statistics of the CG and TG for outcome
measures before and after Step 1 and Step 2 treatment
are reported in Additional file 1: Table S1. Depending on
the outcome measure, 57–66 families from the CG and
65–77 families from the TG were included.
Results of the final latent growth curve models for stan-
dardized variables are provided for child outcome (Table 1)
and mother outcome (Table 2). Reported are the means of
the latent slope factors for the CG ðαðCGÞ2 ;αðCGÞ3 ) and TG ð
αðTGÞ2 ; α
ðTGÞ
3 ), which represent change in groups during Step
1 and Step 2. The results concern the final models after
constraints among the means of the latent factors had been
tested in the within- and the between-group analysis. All
coefficients with an asterisk (*) indicate that the means are
significantly different from zero. Further, coefficients of
equal size indicate equality constraints among the parame-
ters and show that the parameters did not significantly dif-
fer across time or group. For example, for K-SADS ODD
(Table 1), change rates across groups and periods were all
considered to be equal except for the CG during the Step 2
treatment (αðCGÞ2 = α
ðTGÞ
2 = α
ðTGÞ
3 = − 0.16; α
ðCGÞ
3 = − 0.53).
Although the within- and between-group analyses were
integrated, for reasons of convenience, the results are
described separately in the following.
Results for unstandardized variables of child and mother
outcome are provided in Additional file 1: Table S2. This
table also contains additional information about model fit
(χ2 test, CFI) and the means of the latent intercept factor α1.
Within-group analysis
In the within-group analysis, the equality of the Step 1
and Step 2 slope factor means was tested within the
groups. This primarily served as a test for the additional
effects of the Step 2 parent-child training in the TG and
the CG after the Step 1 treatment of the mother. In the
CG and for child outcome (Table 1), αðCGÞ2 and α
ðCGÞ
3 did
not significantly differ, except for child disruptive behav-
ior rated by the blinded clinician (K-SADS ODD) and
the mother (SDQ Conduct). For these two measures, a
stronger symptom decrease was observed during the
Step 2 parent-child training compared to the previous
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Step 1 treatment of the mother, indicating additional
treatment effects of the parent-child training in the CG.
For mother outcome in the CG (Table 2), no differences
between αðCGÞ2 and α
ðCGÞ
3 were detected.
Regarding the TG and child outcome (Table 1), no differ-
ences between αðTGÞ2 and α
ðTGÞ
3 were found, and therefore
no evidence for any additional effect of the parent-child
training after the Step 1 intensive treatment of the mother.
In contrast, varying change rates in the TG during
Step 1 and Step 2 were obtained for ADHD symptoms
of the mothers (Table 2) rated by the blinded clinician
(CAARS–O Inattention, CAARS–O Impulsivity) and the
mothers themselves (CAARS–S Inattention, CAARS–S
Hyperactivity, CAARS–S Impulsivity). Both informants
reported a stronger symptom reduction during the Step 1
treatment of the mother compared to the Step 2
parent-child training.
Between-group analysis
This analysis considered two comparisons: First, the con-
trast of the Step 1 slope factor means of the CG and TG
(H0: α
ðCGÞ
2 = α
ðTGÞ
2 ) and second, the comparison of the Step
2 factor means of both groups (H0: α
ðCGÞ
3 = α
ðTGÞ
3 ). The
Step 1 comparison was of particular interest for this ana-
lysis, as it served as a test for the efficacy of the intensive
treatment of the mother in the TG relative to the CG. For
child outcome (Table 1), differences between groups were
detected only for disruptive behavior during Step 1 in
ratings of the mothers (SDQ Conduct) and during Step 2
in ratings of the blinded clinicians (K-SADS ODD). More
specifically, throughout Step 1, mothers of the CG
reported no symptom change, while mothers of the TG
rated a reduction (SDQ Conduct). This indicated the
efficacy of the intensive treatment of the mother in the
TG relative to the CG regarding the child’s disruptive be-
havior. In ratings of the blinded clinicians, group differ-
ences emerged at Step 2 during parent-child training and
were in favor of the CG in terms of a stronger reduction
of disruptive behavior (K-SADS ODD).
Table 2 Change in Mother Outcome Variables During Step 1
Treatment of the Mother and Step 2 Parent-Child Training for
Standardized Variables
Outcome & informant Control group Treatment group
αðCGÞ2 α
ðCGÞ
3 α
ðTGÞ
2 α
ðTGÞ
3
CAARS–O blinded clinician
Inattention −0.19* − 0.19* − 0.60* − 0.19*
Hyperactivity − 0.20* − 0.20* − 0.35* − 0.35*
Impulsivity − 0.25* − 0.25* − 0.62* − 0.25*
CAARS–S mother
Inattention −0.18* − 0.18* − 0.58* − 0.18*
Hyperactivity − 0.24* − 0.24* − 0.55* − 0.24*
Impulsivity − 0.23* − 0.23* − 0.62* − 0.23*
Note. Results concern the final model of a series of nested piecewise linear
latent growth models (within- and between-group analysis). In the case of
equal coefficients, change rates did not significantly differ across treatment
groups and/or steps and were constrained to be equal. αðCGÞ2 = mean of latent
slope factor representing average change in CG during Step 1 (T1 to T2); αðCGÞ3 =
mean of latent slope factor indicating average change in CG during Step 2 (T2 to
T3); αðTGÞ2 = mean of latent slope factor representing average change in TG during
Step 1 (T1 to T2); αðTGÞ3 = mean of latent slope factor indicating average change in
TG during Step 2 (T2 to T3); CAARS–O Conners’ Adult ADHD Rating Scales–
Observer: Long Version with the scales Inattention and Memory Problems,
Hyperactivity/Restlessness and Impulsivity/Emotional Lability, CAARS–S Conners’
Adult ADHD Rating Scales–Self-Report: Long Version with scales analogous
to CAARS–O
*p < .05
Table 1 Change in Child Outcome Variables During Step 1
Treatment of the Mother and Step 2 Parent-Child Training
for Standardized Variables
Outcome & informant Control group Treatment group
αðCGÞ2 α
ðCGÞ
3 α
ðTGÞ
2 α
ðTGÞ
3
K-SADS blinded clinician
Inattention −0.42* − 0.42* − 0.42* − 0.42*
Hyp/Imp − 0.25* − 0.25* − 0.25* − 0.25*
ODD − 0.16* − 0.53* − 0.16* − 0.16*
SDQ mother
Hyperactivity −0.30* − 0.30* − 0.30* − 0.30*
Conduct − 0.05 −0.24* − 0.24* − 0.24*
Emotional − 0.19* − 0.19* − 0.19* − 0.19*
HSQ mother
Total −0.27* − 0.27* − 0.27* − 0.27*
FIQ mother
Social −0.14* − 0.14* − 0.14* − 0.14*
Negative − 0.20* − 0.20* − 0.20* − 0.20*
Positive 0.04 0.04 0.04 0.04
SDQ teacher
Hyperactivity −0.11* − 0.11* − 0.11* − 0.11*
Conduct − 0.17* − 0.17* − 0.17* − 0.17*
Emotional − 0.13* − 0.13* − 0.13* − 0.13*
Note. Results concern the final model of a series of nested piecewise linear
latent growth models (within- and between-group analysis). In the case of
equal coefficients (i.e., α2 and α3 in TG and CG), change rates did not significantly
differ across treatment groups and/or steps and were constrained to be equal.
αðCGÞ2 = mean of latent slope factor representing average change in CG during
Step 1 (T1 to T2); αðCGÞ3 = mean of latent slope factor indicating average change
in CG during Step 2 (T2 to T3); αðTGÞ2 = mean of latent slope factor representing
average change in TG during Step 1 (T1 to T2); αðTGÞ3 = mean of latent
slope factor indicating average change in TG during Step 2 (T2 to T3); K-
SADS Kiddie-Sads-Present and Lifetime Version with the scales Inattention,
Hyperactivity/Impulsivity and Oppositional defiant disorder, SDQ Strengths
and Difficulties Questionnaire with the scales Hyperactivity, Conduct
Problems and Emotional Symptoms, HSQ Home Situation Questionnaire, FIQ
Family Impact Questionnaire with the scales Impact on Social Life, Positive
Feelings Toward Child and Negative Feelings Toward Child
*p < .05
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With respect to ADHD symptoms of mothers (Table 2)
during Step 1, there was a consistent treatment advantage
for the TG in ratings of the blinded clinicians (CAARS–O
Inattention, CAARS-O Hyperactivity, CAARS–O Impulsiv-
ity) as well as in reports of the mothers (CAARS–S Inatten-
tion, CAARS-S Hyperactivity, CAARS–S Impulsivity).
Subsequently, during Step 2, the TG benefit was only
assessed for hyperactivity reported by the blinded clinicians
(CAARS-O Hyperactivity).
Effect size and informants
Factor means (αðCGÞ2 , α
ðCGÞ
3 , α
ðTGÞ
2 , α
ðTGÞ
3 Þ of the standard-
ized observed variables (Tables 1 and 2) were considered
as effect size measures and were interpreted like Cohen’s
d (see Statistical analysis section). The effect sizes varied
depending on different factors including the outcome
measure, the informant, and the treatment period. For
child symptoms (Table 1), on a descriptive level, the
strongest change was observed for disruptive behavior in
the CG during Step 2 as rated by the blinded clinician,
with an effect size in the medium range (K-SADS ODD).
In contrast, as expected, teachers reported comparatively
low effect sizes for child symptoms in general (SDQ).
For ADHD symptoms of the mother (Table 2), the most
pronounced change was detected in the TG during Step
1 treatment of the mother rated by the blinded clinicians
(CAARS–O) as well as the mothers (CAARS–S), with
effect sizes in the medium range.
Model fit and intercept factor
Model fit criteria were not fulfilled for all outcome vari-
ables in multi-group analysis (Additional file 1: Table
S2). Therefore, for each variable, we inspected which
group (CG, TG) was the source for insufficient model fit
and did not achieve model fit criteria when analyzed in
single-group analysis. However, we refrained from any
post-hoc model specifications because the consideration
of correlated residuals often resulted in model errors.
The between-group analysis also included a comparison
of the intercept factor means α1 that indicated the average
outcome at baseline (Additional file 1: Table S2). Except
for one scale in mother rating (FIQ Social), no group dif-
ferences were detected between the CG and TG.
Discussion
The AIMAC study aimed to test, in a randomized trial,
whether an intensive treatment for mothers with ADHD
including pharmacotherapy and group psychotherapy,
improves outcomes for ADHD parent-child training.
Previous analyses showed that ADHD symptoms could
be successfully reduced in mothers with intensive Step 1
treatment compared to minimal treatment. However, the
combination of intensive treatment of the mother and
subsequent parent-child training revealed no treatment
advantage regarding ADHD symptoms and disruptive
behavior of the child [32].
This secondary analysis was particularly concerned
with the efficacy of the parent-child training in the
AIMAC study. The results of our analysis suggest that
the parent-child training may be a valid treatment option
and may help to reduce the disruptive behavior (but not
ADHD symptoms) of the child even for mothers who
are not intensively treated beforehand. This can be con-
cluded from the within-group analysis of the CG in re-
ports of the blinded clinician and the mothers (CG: Step
1 vs. Step 2). The results are of practical importance as
they suggest that children’s disruptive behavior may im-
prove from parent-child training even if the mothers still
show ADHD symptoms and do not receive the best
available treatment in advance. Previous research find-
ings on this topic have been mixed [5, 6]. As suggested
in previous reviews, the positive results in this trial may
be explained by the personalized approach we used in
order to accommodate the training to the needs of the
parents [5]. The individualized treatment planning may
have helped the mothers to compensate for ADHD-re-
lated deficits and to participate in the training.
The efficacy of the parent-child training in the CG
may also contribute to the understanding of why, in pre-
vious studies, the two treatment groups may not have
differed when the total change across both treatment
steps was analyzed [32]. Our results suggest that what
the CG may have missed out on in terms of improve-
ment during the first phase of the study (due to the
lower intensity of the treatment of the mother), was
likely made up for during the second phase when the
parent-child training was offered. For the TG, by con-
trast, there is a tendency, across informants, that the
improvement of the disruptive behavior already began
earlier, during the treatment of the mother, and was
more equally distributed over the two treatment steps.
TG families might therefore have had less room for im-
provement at the beginning of the parent-child training.
Furthermore, although we found no evidence for an add-
itional effect of the parent-child training in the TG, we
would not conclude that this treatment approach was
less relevant for these children. The parent-child training
might have been important to maintain the initial Step 1
treatment gains, and the limitations of our analytical
approach have to be considered (see limitations section).
The second research question concerned the efficacy
of the intensive treatment of the mother (pharmacother-
apy, psychotherapy) regarding child symptoms. Com-
pared to supportive counseling in the CG, children of
the TG showed a treatment advantage regarding disrup-
tive behavior in the ratings of the mothers at the end of
the first treatment phase (Step 1: TG vs. CG). To our
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knowledge, this is the first study to demonstrate a treat-
ment advantage of the combined effect of adult pharma-
cotherapy and psychotherapy on the child outcome. We
consider this finding to be robust, as we tested against
an active control condition in which at least some com-
mon treatment factors were realized (e.g., hope, thera-
peutic alliance). One might speculate further that the
effect of the adult treatment in the TG on the disruptive
behavior of the child was mediated by improved parent-
ing practices, which are considered to be the link be-
tween neuropsychological functioning of the parent and
the psychopathology of the child [11]. However, the ef-
fect of the adult treatment on the child was rather small.
Positive effects for child disruptive behavior were ob-
served in ratings of the blinded clinician and the mother
but not in teacher ratings. The latter may be explained
by a lack of generalization of the improvement to differ-
ent settings. This is a common finding and has been
reported in other studies as well [58]. Although we con-
sider the blinded clinician perspective to be valuable,
restrictions also need to be considered here. As clinical
ratings were largely based on a parent interview, their
assessment might have been biased towards the perspec-
tive of the mother [32].
Of further interest is our observation of a reduction
of child ADHD symptoms in both treatment groups.
For each treatment group and step, the improvement
was in the small to medium range for ratings of the
blinded clinician and the mothers. For ratings of the
teachers, the effects were negligible. However, we
could not highlight any group or phase to be superior
to the other (within- and between-group comparison).
As a consequence, the internal validity of the findings
is low and the results remain somewhat inconclusive.
It might be that all interventions are effective, but it
is not possible to estimate their treatment advantage
compared to merely waiting, and other explanations
for the symptom reductions are possible as well (e.g.,
regression to the mean).
One potentially important factor in explaining these re-
sults for child ADHD symptoms is child pharmacotherapy
which already existed before the trial. Three quarters of
the children were maintained on medication throughout
the study. As indicated by rather low baseline values, this
probably reduced the room for improvement in child
ADHD symptoms and consequently the likelihood of de-
tecting treatment effects. For many children, the results
therefore rather reflect the additional effect of study treat-
ments beyond that of an existing medication. However, in
recent moderator analyses, ongoing child medication was
found to have no explanatory power [59].
This study has several limitations. First, the analysis
relied in part on a within-group control design, which
is less optimal for drawing firm conclusions than the
randomized between-group comparison. To test the
additional treatment effect of the parent-child training,
the change rates of the two treatment phases were con-
trasted. This test is based implicitly on the assumption
that the change during the first step is maintained in
the second step, which in our case was a very conserva-
tive assumption particularly for the efficacy of the par-
ent-child training in the TG. Second, model fit criteria
were quite liberal and, moreover, were not reached in
all outcome variables. Multiple factors may be respon-
sible for misfit in growth curve models [60, 61], includ-
ing misspecifications in the mean structures (e.g.,
functional form of the mean growth trajectory) and the
covariance structures (e.g., covariance of residuals). As
change during Step 1 and Step 2 was determined by
two assessment points only, we could not investi-
gate other growth forms besides the linear models. We
also abstained from any post-hoc model modifications
regarding the covariance structure (e.g., adding corre-
lated residuals), because the consideration of correlated
residuals often resulted in model errors. Furthermore,
we were primarily interested in the mean growth trajec-
tory, which is less affected by possible misspecifications
in the covariance structure [60]. Third, our results do
not always completely correspond to previous findings
of the study (e.g., SDQ Conduct) [32]. Among other
things, this is due to differences in the research ques-
tion and varying statistical models. In Jans et al. [32]
the focus was on the between-group differences (CG vs.
TG). For this a linear regression approach was used
and the outcome at certain time points was predicted
by the treatment group along with other covariates in-
cluding the baseline assessment. In contrast for the
current analysis we also were interested in the
within-group perspective (Step 1 vs. Step 2 in CG and
TG). For this change scores (T1 to T2; T2 to T3) were
estimated by piecewise latent growth curve models that
could be contrasted not only between but also within
the treatment groups. A detailed discussion about other
and more general concerns regarding this study has
been provided elsewhere [32, 62].
Conclusions
We conclude from our findings that parent-child train-
ing may be effective to reduce children’s disruptive be-
havior even if parental ADHD is not intensively treated
beforehand. This is in contrast to some previous find-
ings. The discrepant results may be explained by differ-
ent methodological approaches, although we hypothesize
that the positive effects in this analysis were mainly
attributable to the fact that the parent-child training was
individualized, which may have helped the parents to
compensate for ADHD-related deficits and to enhance
their treatment participation. Future studies should
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investigate the importance of personalized treatment ap-
proaches for parents with ADHD in more detail and
under experimental control. We also found that the
combination of pharmacotherapy and psychotherapy for
mothers improved children’s disruptive behavior, at least
from the perspective of the participating mothers. How-
ever, the effects were rather small and may not be suffi-
cient to fully support the child. This finding is in line
with previous studies investigating the effect of adult
pharmacotherapy on children in isolation. The results of
our analysis add to the existing knowledge that even a
multimodal approach for ADHD in parents might not
be sufficient for their children. Therefore, if both parent
and child are diagnosed with ADHD, a child-centered
approach is recommended in any case.
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